Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 4Unknown 3Completed 3Active not recruiting 2Withdrawn 1Approved for marketing 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Observational 2Interventional 1

Sponsor

Conditions

Breast Neoplasms 1871Neoplasms 1257Colorectal Neoplasms 1057Carcinoma, Non-Small-Cell Lung 1012Stomach Neoplasms 802Carcinoma, Hepatocellular 785Lung Neoplasms 769Prostatic Neoplasms 697Pancreatic Neoplasms 577Rectal Neoplasms 449Ovarian Neoplasms 406Colonic Neoplasms 405Neoplasm Metastasis 403Uterine Cervical Neoplasms 400Recurrence 382Leukemia, Myeloid, Acute 372Esophageal Neoplasms 363Multiple Myeloma 339Lymphoma 335Head and Neck Neoplasms 330Melanoma 312Precursor Cell Lymphoblastic Leukemia-Lymphoma 292Brain Neoplasms 264Urinary Bladder Neoplasms 256Liver Neoplasms 225Nasopharyngeal Carcinoma 223Leukemia 218Lymphoma, Large B-Cell, Diffuse 216Polycystic Ovary Syndrome 210Squamous Cell Carcinoma of Head and Neck 205

Interventions

Sirolimus 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Perivascular Epithelioid Cell Neoplasms × Clear all
NCT05625919 2022-11-28

A Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1/2 Unknown
54 enrolled

Perivascular Epithelioid Cell Neoplasms

NCT05617105 2022-11-15

PEComesCells

University Hospital, Strasbourg, France

Unknown
100 enrolled

Lymphangioleiomyomatosis, Angiomyolipoma, Perivascular Epithelioid Cell Neoplasms

NCT03916575 2019-05-01

PEComas

University Hospital, Strasbourg, France

Unknown
60 enrolled

Perivascular Epithelioid Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡